Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-273-8 | CAS number: 56-41-7
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
A toxicokinetic statement was drawn up.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
The excerpt from the toxicokinetic statement is:
The concentration of L-alanine in blood is relatively constant. For risk assessment purposes oral absorption
of L-alanine is set at 100%.
L-alanine is of low volatility due to a very low vapour pressure (0.00000283 Pa). From this and from the
particle size it is not expected that L-alanine reaches the nasopharyncheal region or subsequently the
tracheobronchial or pulmonary region in significant amounts.
However, being a very hydrophilic substance with a molecular mass of only 89.09, any L-alanine reaching
the lungs might be absorbed through aqueous pores. For risk assessment purposes, although it is unlikely
that L-alanine will be available to a high extent after inhalation via the lungs due to the low vapour pressure
and high MMAD (Mass median aerodynamic diameter), the inhalation absorption of L-alanine is set at 100%.
L-alanine with high water solubility (166.5 g/L) and the log P value below 0 (-2.74) may be too hydrophilic to
cross the lipid rich environment of the stratum corneum. Therefore, 10% dermal absorption of L-alanine is
proposed for risk assessment purposes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
